{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:17:03Z","timestamp":1783077423375,"version":"3.54.6"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jtos.2021.11.002","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T21:22:34Z","timestamp":1636492954000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops (\u201cTriple Play\u201d) in Recalcitrant Immunological Ocular Surface Diseases"],"prefix":"10.1016","volume":"23","author":[{"given":"Eitan A.","family":"Katz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0291-7504","authenticated-orcid":false,"given":"Sarah","family":"Sunshine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6642-3418","authenticated-orcid":false,"given":"Monazzah","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayasgalan","family":"Surenkhuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6444-2954","authenticated-orcid":false,"given":"Anubhav","family":"Pradeep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtos.2021.11.002_bib1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","article-title":"TFOS DEWS II pain and sensation report","volume":"15","author":"Belmonte","year":"2017","journal-title":"Ocul Surf"},{"issue":"5","key":"10.1016\/j.jtos.2021.11.002_bib2","article-title":"NK cells promote th-17 mediated corneal barrier disruption in dry eye","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jtos.2021.11.002_bib3","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1189\/jlb.1110611","article-title":"Interferon-\u03b3-secreting NK cells promote induction of dry eye disease","volume":"89","author":"Chen","year":"2011","journal-title":"J Leukoc Biol"},{"issue":"4","key":"10.1016\/j.jtos.2021.11.002_bib4","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1167\/iovs.11-9299","article-title":"Autoantibodies contribute to the immunopathogenesis of experimental dry eye disease","volume":"53","author":"Stern","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"12","key":"10.1016\/j.jtos.2021.11.002_bib5","doi-asserted-by":"crossref","first-page":"7961","DOI":"10.1167\/iovs.14-15332","article-title":"Hyperosmolar stress induces neutrophil extracellular trap formation: implications for dry eye disease","volume":"55","author":"Tibrewal","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/j.jtos.2021.11.002_bib6","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1167\/iovs.08-2417","article-title":"Characterization of effector T cells in dry eye disease","volume":"50","author":"El Annan","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.jtos.2021.11.002_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.autrev.2012.07.018","article-title":"Autoinflammation and autoimmunity: bridging the divide","volume":"12","author":"Doria","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.jtos.2021.11.002_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jtos.2019.10.004","article-title":"Pathological consequences of anti-citrullinated protein antibodies in tear fluid and therapeutic potential of pooled human immune globulin-eye drops in dry eye disease","volume":"18","author":"Kwon","year":"2020","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.jtos.2021.11.002_bib9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"issue":"2","key":"10.1016\/j.jtos.2021.11.002_bib10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/09273940701299354","article-title":"Systemic immunomodulatory therapy in severe dry eye secondary to inflammation","volume":"15","author":"Cordero-Coma","year":"2007","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"10.1016\/j.jtos.2021.11.002_bib11","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology (Rochester, Minn.)"},{"issue":"5","key":"10.1016\/j.jtos.2021.11.002_bib12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ophtha.2003.08.034","article-title":"Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety","volume":"111","author":"Durrani","year":"2004","journal-title":"Ophthalmology (Rochester, Minn.)"},{"issue":"9","key":"10.1016\/j.jtos.2021.11.002_bib13","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1167\/iovs.07-0491","article-title":"Efficacy of topical immunoglobulins against experimental adenoviral ocular infection","volume":"48","author":"Nwanegbo","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2021.11.002_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jtos.2021.02.004","article-title":"Ocular surface disease associated with immune checkpoint inhibitor therapy","volume":"20","author":"Park","year":"2021","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2021.11.002_bib15","series-title":"2000 Feb 29 - . Identifier NCT04510428, OSIG-eye Drops Treatment for Dry Eye Disease","year":"2020"},{"issue":"1","key":"10.1016\/j.jtos.2021.11.002_bib16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archophthalmol.2009.356","article-title":"Minimal clinically important difference for the ocular surface disease index","volume":"128","author":"Miller","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.jtos.2021.11.002_bib17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/biomedicines8090344","article-title":"Inflammation in dry eye syndrome: identification and targeting of oxylipin-mediated mechanisms","volume":"8","author":"Chistyakov","year":"2020","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.jtos.2021.11.002_bib18","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.exer.2008.11.035","article-title":"sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised","volume":"88","author":"Chen","year":"2009","journal-title":"Exp Eye Res"},{"issue":"1","key":"10.1016\/j.jtos.2021.11.002_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29568-3","article-title":"Tear eicosanoids in healthy people and ocular surface disease","volume":"8","author":"Ambaw","year":"2018","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jtos.2021.11.002_bib20","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ajpath.2011.06.030","article-title":"Desiccating stress induces CD4+ T-Cell\u2013Mediated sj\u00f6gren's Syndrome\u2013Like corneal epithelial apoptosis via activation of the extrinsic apoptotic pathway by interferon-\u03b3","volume":"179","author":"Zhang","year":"2011","journal-title":"Am J Pathol"},{"issue":"13","key":"10.1016\/j.jtos.2021.11.002_bib21","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1167\/iovs.12-10430","article-title":"Ocular surface extracellular DNA and nuclease activity imbalance: a new paradigm for inflammation in dry eye disease","volume":"53","author":"Sonawane","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.jtos.2021.11.002_bib22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/rheumatology\/kep357","article-title":"Age-related T-cell cytokine profile parallels corneal disease severity in sj\u00f6gren's syndrome-like keratoconjunctivitis sicca in CD25KO mice","volume":"49","author":"De Paiva","year":"2010","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.jtos.2021.11.002_bib23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/ICO.0000000000000721","article-title":"Differential profiling of T-cell cytokines as measured by protein microarray across dry eye subgroups","volume":"35","author":"Meadows","year":"2016","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2021.11.002_bib24","first-page":"583","article-title":"Upregulation of the IL-33\/ST2 pathway in dry eye","volume":"25","author":"Wang","year":"2019","journal-title":"Mol Vis"},{"issue":"3","key":"10.1016\/j.jtos.2021.11.002_bib25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jtos.2019.03.010","article-title":"Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: implications for novel biomarkers and therapeutic strategies","volume":"17","author":"An","year":"2019","journal-title":"Ocul Surf"},{"issue":"7","key":"10.1016\/j.jtos.2021.11.002_bib26","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1167\/iovs.09-3684","article-title":"Regulation of T-cell chemotaxis by programmed death-ligand 1 (PD-L1) in dry Eye\u2013Associated corneal inflammation","volume":"51","author":"El Annan","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jtos.2021.11.002_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107724","article-title":"Ocular mucins in dry eye disease","volume":"186","author":"Portal","year":"2019","journal-title":"Exp Eye Res"},{"issue":"6","key":"10.1016\/j.jtos.2021.11.002_bib28","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ajpath.2016.02.004","article-title":"Interferon-\u03b3\u2013Induced unfolded protein response in conjunctival goblet cells as a cause of mucin deficiency in sj\u00f6gren syndrome","volume":"186","author":"Coursey","year":"2016","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.jtos.2021.11.002_bib29","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1167\/iovs.14-13864","article-title":"Infrared imaging of meibomian glands and evaluation of the lipid layer in sj\u00f6gren's syndrome patients and nondry eye controls","volume":"56","author":"Menzies","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.jtos.2021.11.002_bib30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3349\/ymj.2014.55.1.203","article-title":"Inflammatory cytokine and osmolarity changes in the tears of dry eye patients treated with topical 1% methylprednisolone","volume":"55","author":"Lee","year":"2014","journal-title":"Yonsei Med J"},{"issue":"3","key":"10.1016\/j.jtos.2021.11.002_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/bbmt.2002.v8.pm11939601","article-title":"Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation","volume":"8","author":"Sokos","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtos.2021.11.002_bib32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1385\/CRIAI:29:3:219","article-title":"Intravenous immunoglobulin therapy and systemic lupus erythematosus","volume":"29","author":"Zandman-Goddard","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.jtos.2021.11.002_bib33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/s10165-009-0180-2","article-title":"Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary sj\u00f6gren\u2019s syndrome","volume":"19","author":"Wakasugi","year":"2009","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.jtos.2021.11.002_bib34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00002281-200305000-00010","article-title":"Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it?","volume":"15","author":"Braun-Moscovici","year":"2003","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.jtos.2021.11.002_bib35","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/ard.54.5.382","article-title":"Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines","volume":"54","author":"Muscat","year":"1995","journal-title":"Ann Rheum Dis"},{"issue":"29","key":"10.1016\/j.jtos.2021.11.002_bib36","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.2174\/138161211798157540","article-title":"Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in autoimmune diseases","volume":"17","author":"Katz","year":"2011","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.jtos.2021.11.002_bib37","article-title":"Intravenous immunoglobulins: mode of action and indications in autoimmune and inflammatory dermatoses","author":"Dourmishev","year":"2016","journal-title":"Int J Inflamm"},{"issue":"2","key":"10.1016\/j.jtos.2021.11.002_bib38","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10875-012-9816-7","article-title":"Broadened T-cell repertoire diversity in ivIg-treated SLE patients is also related to the individual status of regulatory T-cells","volume":"33","author":"Costa","year":"2013","journal-title":"J Clin Immunol"},{"issue":"2","key":"10.1016\/j.jtos.2021.11.002_bib39","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1034\/j.1600-6143.2003.00011.x","article-title":"Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells","volume":"3","author":"Toyoda","year":"2003","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.jtos.2021.11.002_bib40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1600-065X.1994.tb00858.x","article-title":"V Region\u2010Mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.ig)","volume":"139","author":"Kazatchkine","year":"1994","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.jtos.2021.11.002_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-01404-0","article-title":"IVIG regulates the survival of human but not mouse neutrophils","volume":"7","author":"Schneider","year":"2017","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.jtos.2021.11.002_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026469","article-title":"A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms","volume":"6","author":"Casulli","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jtos.2021.11.002_bib43","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00002826-200311000-00009","article-title":"Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders","volume":"26","author":"Matsuda","year":"2003","journal-title":"Clin Neuropharmacol"},{"issue":"13","key":"10.1016\/j.jtos.2021.11.002_bib44","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1182\/blood-2006-05-021568","article-title":"Immunologic and functional evidence for anti-siglec-9 autoantibodies in intravenous immunoglobulin preparations","volume":"108","author":"Von Gunten","year":"2006","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jtos.2021.11.002_bib45","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtos.2021.11.002_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/biom6010015","article-title":"The production processes and biological effects of intravenous immunoglobulin","volume":"6","author":"Barahona Afonso","year":"2016","journal-title":"Biomolecules"},{"issue":"S1","key":"10.1016\/j.jtos.2021.11.002_bib47","first-page":"21","article-title":"Modulation of complement\u2010mediated immune damage by intravenous immune globulin","volume":"104","author":"Basta","year":"1996","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"10.1016\/j.jtos.2021.11.002_bib48","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/bjo.2004.044347","article-title":"Autologous serum eye drops for ocular surface disorders","volume":"88","author":"Geerling","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"14","key":"10.1016\/j.jtos.2021.11.002_bib49","doi-asserted-by":"crossref","first-page":"DES121","DOI":"10.1167\/iovs.17-23760","article-title":"Autologous serum and serum components","volume":"59","author":"Higuchi","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.jtos.2021.11.002_bib50","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0091-6749(99)70466-5","article-title":"Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin","volume":"103","author":"Spahn","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.jtos.2021.11.002_bib51","doi-asserted-by":"crossref","first-page":"P286","DOI":"10.1016\/j.ophtha.2018.10.023","article-title":"Dry eye syndrome preferred practice pattern","volume":"126","author":"Akpek","year":"2019","journal-title":"Ophthalmology (Rochester, Minn.)"},{"issue":"4","key":"10.1016\/j.jtos.2021.11.002_bib52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/ICU.0000000000000171","article-title":"Scleral lens use in dry eye syndrome","volume":"26","author":"Bavinger","year":"2015","journal-title":"Curr Opin Ophthalmol"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012421001294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012421001294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:42:04Z","timestamp":1761540124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012421001294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":52,"alternative-id":["S1542012421001294"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2021.11.002","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combinatorial therapy with immunosuppressive, immunomodulatory and tear substitute eyedrops (\u201cTriple Play\u201d) in Recalcitrant Immunological Ocular Surface Diseases","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2021.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}